A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire

por Tillett, William, Lin, Chen-Yen, Zbrozek, Art, Sprabery, Aubrey Trevelin, Birt, Julie
Publicado 2019

Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors

por Kirkham, Bruce, Sesin, Carlos, Gellett, Amanda M., Sprabery, Aubrey T., Lin, Chen-Yen, Turkiewicz, Anthony
Publicado 2021

Impact of Enthesitis on Psoriatic Arthritis Patient-Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey

por Orbai, Ana-Maria, Birt, Julie A., Holdsworth, Elizabeth A., Booth, Nicola, Malatestinic, William N., Sprabery, Aubrey T., Reginato, Anthony M.
Publicado 2020

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure

por Deodhar, Atul A, Combe, Bernard, Accioly, Ana P, Bolce, Rebecca, Zhu, Danting, Gellett, Amanda M, Sprabery, Aubrey Trevelin, Burmester, Gerd-Rüdiger R
Publicado 2022

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

por Combe, Bernard, Tsai, Tsen-Fang, Huffstutter, J. Eugene, Sprabery, Aubrey Trevelin, Lin, Chen-Yen, Park, So Young, Kronbergs, Andris, Hufford, Matthew M., Nash, Peter
Publicado 2021

Real‐World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study

por Murage, Mwangi J., Princic, Nicole, Park, Julie, Malatestinic, William, Zhu, Baojin, Atiya, Bilal, Kern, Scott A., Stenger, Keri B., Sprabery, Aubrey Trevelin, Ogdie, Alexis
Publicado 2021

Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs

por Murage, Mwangi J, Princic, Nicole, Park, Julie, Malatestinic, William N, Zhu, Baojin, Atiya, Bilal, Kern, Scott A, Stenger, Keri B, Sprabery, Aubrey Trevelin, Ogdie, Alexis
Publicado 2022

Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials

por Eder, Lihi, Tony, Hans-Peter, Odhav, Satish, Agirregoikoa, Eva Galindez, Korkosz, Mariusz, Schwartzman, Sergio, Sprabery, Aubrey Trevelin, Gellett, Amanda M., Park, So Young, Bertram, Clinton C., Ogdie, Alexis
Publicado 2022

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

por Chandran, Vinod, van der Heijde, Désirée, Fleischmann, Roy M, Lespessailles, Eric, Helliwell, Philip S, Kameda, Hideto, Burgos-Vargas, Ruben, Erickson, Janelle S, Rathmann, Suchitrita S, Sprabery, Aubrey Trevelin, Birt, Julie A, Shuler, Catherine L, Gallo, Gaia
Publicado 2020

Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study

por Smolen, Josef S., Sebba, Anthony, Ruderman, Eric M., Schulze-Koops, Hendrik, Sapin, Christophe, Gellett, Amanda M., Sprabery, Aubrey Trevelin, Li, Lingnan, de la Torre, Inmaculada, Gallo, Gaia, Liu-Leage, Soyi, Pillai, Sreekumar, Reis, Paulo, Nash, Peter
Publicado 2020

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)

por Orbai, Ana-Maria, Gratacós, Jordi, Turkiewicz, Anthony, Hall, Stephen, Dokoupilova, Eva, Combe, Bernard, Nash, Peter, Gallo, Gaia, Bertram, Clinton C., Gellett, Amanda M., Sprabery, Aubrey Trevelin, Birt, Julie, Macpherson, Lisa, Geneus, Vladimir J., Constantin, Arnaud
Publicado 2020